Yesterday, September 24, the FDA approved the combination of belzutifan (WELIREG; Merck) plus lenvatinib (LENVIMA; Eisai) to ...
Sophy Levine, PharmD, discusses how an integrated health system specialty pharmacy may help lower 1-year GLP-1 discontinuation.
Safety-net claims emphasize disproportionate Medicaid and uncompensated care borne by 340B hospitals, whereas other analyses ...
Seshadri, MD, speaks on CLL's shift toward fixed-duration, MRD-guided regimens, MRD testing barriers, and open questions on ...
Regulatory volatility since 2020, including IRA price negotiation, MFN pricing directives, and Medicaid best-price dynamics, ...
Community oncology practices face steep structural barriers to clinical trial enrollment, and pragmatic trial design that ...
Prior authorization remains the dominant friction point, with nearly universal reporting of delays that widen the gap between ...
SHAP ranked age, BMI, and vaginal delivery count as dominant contributors, followed by systolic blood pressure, HbA1c, PIR, ...
FDA movement of peptides toward 503A bulks listing advanced despite internal scientific objections citing absent human ...
This study analyzes health care resource utilization and costs among patients with colorectal cancer (CRC) and ovarian cancer ...
She also predicted that drug pricing, more than access algorithms, will determine which GLP-1 becomes first-line within the ...
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened. 259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results